Simplex Trading
DSGN icon

Simplex Trading’s Design Therapeutics DSGN Stock Holding History

Simplex Trading’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-600
Closed -$5.63K – 9309
2025
Q4 		$5.63K Sell
600
-600
-50% -$4.7K ﹤0.01% 7366
2025
Q3 		$9K Buy
+1,200
New +$6.01K ﹤0.01% 7951
2024
Q4 		– Sell
-1,300
Closed -$6K – 8737
2024
Q3 		$6K Buy
1,300
+800
+160% +$3.76K ﹤0.01% 7503
2024
Q2 		$1K Hold
500
– – ﹤0.01% 8452
2024
Q1 		$2K Buy
+500
New +$1.33K ﹤0.01% 8383
2023
Q4 		– Sell
-1,100
Closed -$2K – 9004
2023
Q3 		$2K Buy
+1,100
New +$5.13K ﹤0.01% 8070
2023
Q2 		– Sell
-900
Closed -$5K – 9179
2023
Q1 		$5K Sell
900
-4,000
-82% -$29.9K ﹤0.01% 8027
2022
Q4 		$50K Sell
4,900
-45,700
-90% -$619K ﹤0.01% 5894
2022
Q3 		$846K Buy
+50,600
New +$1.01M ﹤0.01% 2848

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Simplex Trading's DSGN Position: Q2 2025 in Review

Simplex Trading sold out of Design Therapeutics (DSGN) in Q2 2025, closing a stake of 263 shares — an estimated $1K sold.

Simplex Trading first reported a position in DSGN in Q1 2023 and held it in 9 quarters. The position peaked at $40K in Q3 2024. 92 funds tracked by Wall St. Rank hold DSGN as of Q2 2025.

  • Simplex Trading reported no remaining Design Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Simplex Trading sold 263 Design Therapeutics shares in Q2 2025, an estimated $1K.
  • Simplex Trading first reported a position in Design Therapeutics in Q1 2023 and held it in 9 quarters.
  • Simplex Trading's Design Therapeutics position peaked at $40K in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2025.

Based on Simplex Trading's 13F filing for Q2 2025, filed 5 Aug 2025.